AL
ALK-Abello
ALK.CO·CPSEHorsholm DKFounded 19236,000 employees
Mid CappharmaPublicImmunologyRespiratory
Platform: Allergy Immunother
Market Cap
$4B
All Drugs
3
Clinical Trials
7
Failed / Terminated
0
FDA Approved
1
Stock Price & Catalysts (ALK.CO)
Loading ALK.CO stock data...
Drug Pipeline (3 programs)
| Drug Name | Code | Phase | Trials | Modality | Target | MOA | Indications |
|---|---|---|---|---|---|---|---|
| ALK-9856 | ALK-9856 | Approved | 3 | GIP-R | T2DEoE | ||
| Riborelsin | ALK-2579 | Phase 3 | 2 | IL-23 | Huntington'sBCC | ||
| Lisonaritide | ALK-9882 | Phase 1/2 | 2 | AuroraA | HSAS |
SEC Filings & Financial Documents
SEC filings are not available for CPSE-listed companies.
ALK-Abello trades on CPSE (DK). SEC EDGAR only covers US-listed issuers.
Insider Trading Activity
Insider trading data is not available for non-US exchanges.
Catalyst Events (7)